APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase <scp>III</scp> Study Investigating Oliceridine ( <scp>TRV</scp> 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following AbdominoplastyNeil Singla, Eugene R. Viscusi, David Burt et al.|Pain Practice|2019Cited by 183
<p>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the &micro;-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</p>Eugene R. Viscusi, Neil Singla, Emily A. Cook et al.|Journal of Pain Research|2019Cited by 165
APOLLO-1: a Randomized, Controlled, Phase 3 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Pain Following BunionectomyNeil Singla, David G. Soergel, Anthony J. Senagore et al.|The Spine Journal|2017Cited by 4
(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trialsEugene R. Viscusi, Franck Skobieranda, Harold S. Minkowitz et al.|Journal of Pain|2016Cited by 2
I2. Rapid Onset of Pain Relief with Oliceridine (TRV130) vs. Morphine: a Phase 2a/b Study AnalysisDavid G. Soergel, Franck Skobieranda, Lynn R. Webster et al.|Pain Management Nursing|2017Cited by 1